We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 533

What Are the Top Hatch-Waxman and BPCIA Developments for September 2018?
  • Morrison & Foerster LLP
  • USA
  • October 17 2018

This month we highlight the possibility that the Supreme Court will consider the standard for adequacy of written description and a Federal Circuit

Eli Lilly's Effient combination use patent found obvious
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • September 24 2018

The Federal Court recently dismissed Eli Lilly's application for a prohibition order, finding that Apotex's allegation of obviousness of Patent 2,432

Merger control in India
  • Chandhiok & Associates
  • Global, India
  • September 3 2018

A structured guide to merger control laws and practice in India

Playing Fairly in Appeals
  • Marks & Clerk
  • European Union
  • September 3 2018

Following an appeal by both the patentee (Eli Lilly) and the opponent (Dr Armin K. Bohman), the Board of Appeal of the European Patent Office has, in

Patents in the United Kingdom
  • Powell Gilbert LLP
  • United Kingdom, Global
  • September 3 2018

A structured guide to patents law and practice in the United Kingdom

Eli Lilly’s EFFIENT combination use patent found obvious
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • August 27 2018

On July 13, 2018, the Federal Court dismissed Eli Lilly’s application for a prohibition order, finding that Apotex’s allegation of obviousness of

US pharma companies under increasing legislative pressure, key EU SPC decision and much more in July’s life sciences IP round-up
  • IAM
  • USA
  • August 9 2018

In this month’s round-up of patent news from the life sciences, we report on the latest blow to the St Regis Mohawks’ attempt shield their Restasis

How Many Infringers Does It Take to “Administer” a Medication?
  • McDermott Will & Emery
  • USA
  • July 18 2018

Addressing the issue of whether defendant's abbreviated new drug application (ANDA) formulation would infringe plaintiff's method patents under a

Genentech Files Suit Alleging Eli Lilly’s Taltz Product Infringes a Newly Issued Genentech Patent
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • July 16 2018

Taltz was first approved in the United States in 2016 and is currently approved for the treatment of adults with active psoriatic arthritis or

Eli Lilly seeks leave in olanzapine Section 8 damages action
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • July 9 2018

In early 2018 the Federal Court of Appeal dismissed Eli Lilly Canada's appeal of a trial decision awarding more than $70 million to Teva Canada under